Antiandrogens
Aspirin
Bromhexine
Budesonide
Cannabidiol
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Diet
Ensovibep
Exercise
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Proxalutamide
Quercetin
Remdesivir
Sleep
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Famotidine  COVID-19 treatment studies for Famotidine  C19 studies: Famotidine  Famotidine   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Lactoferrin (meta)
Aspirin (meta) Melatonin (meta)
Bamlaniv../e.. (meta) Metformin (meta)
Bebtelovimab (meta) Molnupiravir (meta)
Bromhexine (meta) N-acetylcys.. (meta)
Budesonide (meta) Nigella Sativa (meta)
Cannabidiol (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Peg.. Lambda (meta)
Conv. Plasma (meta) Povidone-Iod.. (meta)
Curcumin (meta) Probiotics (meta)
Diet (meta) Proxalutamide (meta)
Ensitrelvir (meta) Quercetin (meta)
Ensovibep (meta) Remdesivir (meta)
Exercise (meta) Sleep (meta)
Famotidine (meta) Sotrovimab (meta)
Favipiravir (meta) Tixagev../c.. (meta)
Fluvoxamine (meta) Vitamin A (meta)
Hydroxychlor.. (meta) Vitamin C (meta)
Iota-carragee.. (meta) Vitamin D (meta)
Ivermectin (meta) Zinc (meta)

Other Treatments Global Adoption
 
Famotidine COVID-19 studies. Recent:
MacFadden
Fung
Park.
Submit updates/corrections.
May 20
Early, Late, PrEP, PEP Covid Analysis (Preprint) (meta analysis)
meta-analysis
Famotidine for COVID-19: real-time meta analysis of 22 studies
Details   • Statistically significant improvements are seen for mortality, hospitalization, and recovery. 11 studies from 11 independent teams in 5 different countries show statistically significant improvements in isolation (7 for the most serious..
Mar 29
PrEPPEP MacFadden et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofac156
cases, ↓7.0%, p=0.16
Screening Large Population Health Databases for Potential COVID-19 Therapeutics: A Pharmacopeia-Wide Association Study (PWAS) of Commonly Prescribed Medications
Details   Retrospective 26,121 cases and 2,369,020 controls ≥65yo in Canada, showing no significant differences in cases with chronic use of famotidine.
Feb 28
Late Siraj et al., Indian Journal of Clinical Practice, 32:9
death, ↓36.2%, p=0.002
Efficacy of Various Treatment Modalities on Patient-related Outcome in Hospitalized COVID-19 Patients – A Retrospective Study
Details   Retrospective 1,000 COVID+ hospitalized patients in India, showing lower mortality with famotidine and remdesivir in multivariable logistic regression.
Feb 24
Review Kory et al., Journal of Clinical Medicine Research, doi:10.14740/jocmr4658 (Review)
review
“MATH+” Multi-Modal Hospital Treatment Protocol for COVID-19 Infection: Clinical and Scientific Rationale
Details   Review of the data supporting the MATH+ hospital treatment protocol for COVID-19.
Feb 20
Late Pahwani et al., Cureus, doi:10.7759/cureus.22404
death, ↓11.1%, p=1.00
Efficacy of Oral Famotidine in Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2
Details   RCT with 89 famotidine and 89 control patients in Pakistan, showing faster recovery but no significant difference in mortality. 40mg oral famotidine daily.
Feb 10
Early Brennan et al., Gut, doi:10.1136/gutjnl-2022-326952
no recov., ↓48.1%, p=0.23
Oral famotidine versus placebo in non-hospitalised patients with COVID-19: a randomised, double-blind, data-intense, phase 2 clinical trial
Details   Small RCT with 27 famotidine and 28 placebo patients, showing improved recovery with treatment. Recovery was faster with treatment for 14 of 16 symptoms. There was no mortality or hospitalization. NCT04724720.
Jan 17
PrEPPEP Park et al., BMC Pharmacology and Toxicology, doi:10.1186/s40360-022-00549-7 Comparative risk of incidence and clinical outcomes of COVID-19 among proton pump inhibitor and histamine-2 receptor antagonist short-term users: a nationwide retrospective cohort study
Details   Retrospective 62,117 histamine-2 receptor antagonist users in South Korea, showing lower risk of COVID-19 with histamine-2 receptor antagonist use (famotidine, ranitidine, nizatidine, lafutidine, and cimetidine), without statistical signi..
Dec 31
2021
PrEPPEP Wallace et al., BMJ Open, doi:10.1136/bmjopen-2021-050051
death, ↑11.0%, p=0.33
Association of the patterns of use of medications with mortality of COVID-19 infection: a hospital-based observational study
Details   Retrospective 9,532 hospitalized COVID+ veterans in the USA, showing no significant difference in mortality with famotidine use. The study provides results for use before, after, and before+after. Before+after should more accurately repre..
Oct 31
2021
Late Wagner et al., American Journal of Gastroenterology, doi:10.14309/01.ajg.0000779364.64867.ec
death, ↓70.0%, p<0.0001
Famotidine versus Pantoprazole Use and Clinical Outcomes in Patients Hospitalized With COVID-19: A Retrospective Study
Details   Retrospective 2,184 hospitalized patients in the USA, 638 treated with famotidine, showing lower mortality with treatment.
Oct 31
2021
Late Stolow et al., American Journal of Gastroenterology, doi:10.14309/01.ajg.0000778736.01714.cd
death, ↑518.9%, p<0.001
A Retrospective Review: Famotidine Use Is Not Associated With Improved Outcomes in Hospitalized Patients With COVID-19
Details   Retrospective 489 COVID+ hospitalized patients in the USA, showing higher mortality with famotidine treatment.
Oct 25
2021
PrEPPEP Razjouyan et al., Nicotine & Tobacco Research, doi:10.1093/ntr/ntab223
death, ↓27.0%, p=0.006
Smoking Status and Factors associated with COVID-19 In-Hospital Mortality among US Veterans
Details   Retrospective 10,074 veterens in the USA, showing lower mortality with existing famotidine use.
Oct 11
2021
Late Kuno et al., Journal of Medical Virology, doi:10.1002/jmv.27375
death, 0.0%, p=0.97
The association between famotidine and in‐hospital mortality of patients with COVID‐19
Details   PSM retrospective 9,565 COVID-19 hospitalized patients in the USA, 1,593 receiving famotidine, showing no significant difference in mortality.
Oct 1
2021
PrEPPEP Fung et al., PLoS ONE, doi:10.1371/journal.pone.0266922 (preprint 10/1/2021)
death, 0.0%, p=1.00
Effect of common maintenance drugs on the risk and severity of COVID-19 in elderly patients
Details   Retrospective database analysis of 374,229 patients in the USA, showing higher cases, lower hospitalizations, and no change in mortality with famotidine use.
Jul 12
2021
Late Taşdemir et al., Konuralp Tıp Dergisi, doi:10.18521/ktd.935888
death, ↓44.7%, p=0.29
Famotidine in COVID-19 treatment
Details   Retrospective 179 hospitalized patients in Turkey, 85 treated with famotidine and 94 treated with pantoprazole, showing faster recovery with famotidine in unadjusted results.
Apr 30
2021
Late Elhadi et al., PLOS ONE, doi:10.1371/journal.pone.0251085
death, ↓7.1%, p=0.57
Epidemiology, outcomes, and utilization of intensive care unit resources for critically ill COVID-19 patients in Libya: A prospective multi-center cohort study
Details   Prospective study of 465 COVID-19 ICU patients in Libya showing no significant differences with treatment.
Apr 30
2021
PrEPPEP Cheung et al., Gastroenterology, doi:10.1053/j.gastro.2020.05.098
severe case, ↑34.0%, p=0.72
Association Between Famotidine Use and COVID-19 Severity in Hong Kong: A Territory-wide Study
Details   Retrospective 952 COVID-19 patients in Hong Kong, showing no significant difference in severe disease with famotidine use.
Apr 27
2021
Late Samimagham et al., Research Square, doi:10.21203/rs.3.rs-462937/v1 (Preprint)
hosp. time, ↓33.3%, p=0.04
The Efficacy of Famotidine in improvement of outcomes in Hospitalized COVID-19 Patients: A phase III randomised clinical trial
Details   Very small RCT with 20 patients in Iran, showing shorter hospitalization time with famotidine treatment. There was no mortality or ICU admission. Famotidine 160mg four times a day. IRCT20200509047364N2.
Mar 31
2021
Late Mura et al., Signal Transduction and Targeted Therapy, doi:10.1038/s41392-021-00689-y (preprint 3/31/2021)
death, ↓20.9%, p=0.02
Real-world evidence for improved outcomes with histamine antagonists and aspirin in 22,560 COVID-19 patients
Details   PSM retrospective TriNetX database analysis of 1,379 severe COVID-19 patients requiring respiratory support, showing lower mortality with aspirin (not reaching statistical significance) and famotidine, and improved results from the combin..
Mar 8
2021
In Vitro Loffredo et al., Scientific Reports, doi:10.1038/s41598-021-84782-w (In Vitro)
In Vitro
The in-vitro effect of famotidine on SARS-CoV-2 proteases and virus replication
Details   In Vitro study showing that famotidine does not bind or inhibit 3CLpro and PLpro, and no direct antiviral activity was observed with concentrations up to 200µM in Vero E6 and A549 cells.
Feb 28
2021
PrEPPEP Yeramaneni et al., Gastroenterology, doi:10.1053/j.gastro.2020.10.011
death, ↓51.0%, p=0.22
Famotidine Use Is Not Associated With 30-day Mortality: A Coarsened Exact Match Study in 7158 Hospitalized Patients With Coronavirus Disease 2019 From a Large Healthcare System
Details   Retrospective 7,158 hospitalized COVID-19 patients in the USA, showing higher risk or mortality with in-hospital famotidine use and lower risk with pre-existing use, without statistical significance in both cases.
Jan 20
2021
PrEPPEP Balouch et al., Journal of Voice, doi:10.1016/j.jvoice.2021.01.007
symp. case, ↓22.0%, p=0.49
Role of Famotidine and Other Acid Reflux Medications for SARS-CoV-2: A Pilot Study
Details   Survey of 307 patients in the USA, showing no significant difference in COVID-19 cases with famotidine use.
Dec 4
2020
Late Zhou et al., Gut, doi:10.1136/gutjnl-2020-323668
severe case, ↑81.0%, p<0.0001
Proton pump inhibitor or famotidine use and severe COVID-19 disease: a propensity score-matched territory-wide study
Details   Retrospective 4,445 COVID+ patients in China, showing higher risk of combined death/intubation/ICU with famotidine treatment.
Sep 24
2020
Late Shoaibi et al., American Journal of Gastroenterology, doi:10.14309/ajg.0000000000001153 (preprint 9/24/2020)
death, ↑3.0%, p=0.67
Comparative Effectiveness of Famotidine in Hospitalized COVID-19 Patients
Details   Retrospective 1,816 famotidine users and 26,820 non-users hospitalized for COVID-19 in the USA, showing no significant differences with treatment.
Aug 26
2020
PrEPPEP Mather et al., American Journal of Gastroenterology, doi:10.14309/ajg.0000000000000832
death, ↓61.4%, p=0.004
Impact of Famotidine Use on Clinical Outcomes of Hospitalized Patients With COVID-19
Details   PSM retrospective 878 hospitalized patients in the USA, 83 with existing famotidine use, showing significantly lower mortality with treatment.
May 21
2020
PrEPPEP Freedberg et al., Gastroenterology, doi:10.1053/j.gastro.2020.05.053
death/int., ↓57.0%, p=0.02
Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study
Details   PSM retrospective 1,620 hospitalized patients in the USA, 84 with existing famotidine use, showing lower risk of combined death/intubation with treatment.
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit